Beclometasone (Beclomethasone)
(Synonyms: 倍氯米松; Beclomethasone) 目录号 : GC33856
A glucocorticoid
Cas No.:4419-39-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Beclomethasone is a glucocorticoid.1 It reduces plasma corticosteroid levels in rats when administered at doses ranging from 1 to 10 mg/kg.
1.Yamamoto, S.Glucocorticoid action of beclomethasone and its propionate ester derivativesNihon Yakurigaku Zasshi73(1)25-36(1976)
Cell experiment: | The transgenic lines Tg(fli1:GFP) and Tg(mpx:GFP) are used in this study. 0.2 mM N-phenylthiourea (PTU) is applied to prevent pigment formation from 1 day post-fertilization (dpf). For Pu.1 knockdown, Pu.1 MO (1 mM for partial knockdown and 2 mM for complete knockdown is injected into the yolk at the one-cell stage. For pharmacological inhibition, the VEGFR tyrosine kinase inhibitors KRN633 (0.1-1 μM) or Sunitinib (0.1-1 μM), Beclomethasone (25 μM) and β-amino-proprionitrile (βAPN, 500 μM) are applied directly to the egg water and refreshed every 2 days. For pharmacological inhibition, Beclomethasone is applied to the embryos 4 h before implantation and KRN633, Sunitinib and βAPN are applied 4-6 h post-implantation. For each cell line or condition, data are representative of ≥ three independent experiments, with ≥30 embryos/group. Experiments are discarded when the survival rate of the control group is <90%[1]. |
References: [1]. He S, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol. 2012 Aug;227(4):431-45. | |
| Cas No. | 4419-39-0 | SDF | |
| 别名 | 倍氯米松; Beclomethasone | ||
| Canonical SMILES | C[C@@]12[C@](C(CO)=O)(O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C2)=O | ||
| 分子式 | C22H29ClO5 | 分子量 | 408.92 |
| 溶解度 | DMSO : ≥ 32 mg/mL (78.25 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4455 mL | 12.2273 mL | 24.4547 mL |
| 5 mM | 0.4891 mL | 2.4455 mL | 4.8909 mL |
| 10 mM | 0.2445 mL | 1.2227 mL | 2.4455 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet